Jennifer Taubert

J&J accounts for Medicare price talks in 2030 growth projections

As industry attempts to challenge the Inflation Reduction Act falter, Johnson & Johnson is settling into a reality of Medicare drug cost negotiations.

Fraiser Kansteiner Jul 17, 2024 11:02am

J&J keeps the heat on Tremfya's rivals with at-home injector nod

Mar 1, 2019 10:28am

Pharma CEOs in Washington: The latest from the Senate pricing hearing

Feb 26, 2019 12:34pm